Senseonics Holdings Inc. ((SENS)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Senseonics Holdings Inc. used its latest earnings call to paint a picture of a company in rapid commercial ascent but still firmly in investment mode. Management highlighted powerful revenue growth, a surging U.S. patient base and sharply higher margins, while openly acknowledging that heavy spending and cash burn will delay profitability as 2026 becomes a make-or-break scaling year.
Revenue Surges on U.S. Momentum
Senseonics reported full‑year 2025 revenue of $35.3 million, up about 57% from $22.5 million in 2024, underscoring strong adoption of its long‑duration CGM technology. Fourth‑quarter 2025 net revenue jumped 72% to $14.3 million, with U.S. revenue for the year climbing roughly 82% to $27.9 million, cementing the domestic market as the company’s primary growth engine.
Patient and Prescriber Adoption Accelerates
The U.S. patient base more than doubled year over year, reflecting growing awareness and acceptance of Eversense among people with diabetes. New patient starts rose 103% in 2025, while the number of providers actively prescribing the system increased by more than 80%, signaling improving prescriber confidence and a deepening funnel for future growth.
Margins Expand as Scale Kicks In
Gross margins improved dramatically from roughly 25% in the prior period to more than 50% by the end of 2025, showing the benefits of higher volume and better economics. Management expects full‑year 2026 gross profit margins to remain above 50% and to improve sequentially, suggesting further scale efficiencies even as spending ramps.
Commercial Transition Back In‑House
A key milestone was the transition of U.S. commercialization from partner Ascensia back to Senseonics, bringing nearly all domestic commercial employees onto the company’s payroll. Executives described the sales handover as essentially seamless, touting operational efficiencies and cleaner revenue recognition as they move to recognize 100% of revenues themselves.
Regulatory Wins and Pump Integration
On the product front, Senseonics secured CE marking for Eversense 365 in January 2026, unlocking launches in Germany, Italy, Spain and Sweden and broadening its European footprint. The company also launched integration with Sequel’s twiist automated insulin delivery system in February, pairing its 1‑year CGM with an insulin pump and potentially attracting more Type 1 diabetes users.
Aggressive 2026 Revenue Ambitions
Management issued bullish 2026 global net revenue guidance of $58 million to $62 million, implying growth of roughly 65% to 76% over 2025. They expect the acceleration to be fueled by the completed commercial transition, ramping U.S. adoption and a scaling European launch, with international markets becoming an increasingly meaningful slice of the top line.
Balance Sheet Strengthened for Growth
As of December 31, 2025, Senseonics held $94.3 million in cash, restricted cash and equivalents, giving it a cushion to fund its expansion plans. The company also expanded its debt facility with Hercules Capital to as much as $100 million, providing access to about $65 million of additional non‑dilutive capital to support stepped‑up operating expenses.
Pipeline Sets Up Next Product Cycles
Beyond current offerings, the pipeline remains a central part of the growth story, with the Gemini pivotal trial expected to wrap before the end of 2026 and launch targeted for 2027. Management also outlined plans for Freedom in 2028, with Gemini adding a 1‑year battery and flash mode and Freedom enabling direct wireless sensor‑to‑phone communication for a more streamlined user experience.
Operating Expenses Poised to Jump
The growth strategy comes at a steep cost, as Senseonics expects 2026 operating expenses of $150 million to $160 million, roughly a $70 million increase tied to absorbing commercial operations previously handled by Ascensia. While management argues operating leverage will improve over time, investors should anticipate 2026 will be a heavy investment year rather than a profitability inflection point.
High Cash Burn to Fund Expansion
Reflecting the expanded commercial footprint and higher SG&A, the company projects 2026 cash utilization of $110 million to $120 million. This elevated burn rate is driven by in‑house commercialization and global expansion, implying a need for disciplined execution and careful liquidity management as Senseonics works to convert spending into durable revenue growth.
Losses Widen Despite Revenue Growth
Profitability remains elusive, with the fourth‑quarter 2025 net loss widening to $20.8 million, or $0.46 per share, compared with a $15.5 million loss a year earlier. For the full year, the net loss totaled $69.1 million, which management characterized as improved, although Q4 losses expanded due to higher sales commissions and transition‑related commercialization costs.
SG&A Swells on DTC and Sales Costs
Full‑year 2025 SG&A expenses increased by $18.3 million to $52.5 million as the company ramped direct‑to‑consumer marketing and sales support. In the fourth quarter alone, SG&A almost doubled to $19.8 million from $8.9 million, driven by heavier DTC spend, commissions linked to expanded consignment sales, and personnel and transition costs associated with bringing sales in‑house.
Channel Shift and Commission Drag
During the fourth quarter, Senseonics still recognized revenue through its collaboration with Ascensia while expanding consignment, creating temporary complexities in revenue recognition and cost structure. Management noted that higher sales commissions and channel‑mix shifts are near‑term headwinds, but they believe the changes will simplify economics and revenue reporting over the long run.
European Rollout Faces Timing Risks
While CE marking is in hand, management cautioned that the European rollout depends on tender contracts and transition arrangements that may not move in lockstep. They expect most of the transition to occur in the second quarter of 2026, but some tenders and contract negotiations could extend into summer or fall, introducing pacing risk for international revenue ramp‑up.
Seasonality Adds Revenue Volatility
The business remains seasonally weighted toward the back half of the year, with about 40% of 2026 revenue expected in the first half and 60% in the second. First quarter tends to be soft as insurance deductibles reset and patient assistance program use rises, which can intensify quarter‑to‑quarter volatility and pressure near‑term working capital.
Guidance Signals Growth With Heavy Investment
For 2026, Senseonics guided global net revenue of roughly $58 million to $62 million and reiterated a gross profit margin above 50% with sequential improvement, while expecting Europe to furnish about 20% of sales after a second‑quarter rollout. Operating expenses are projected at $150 million to $160 million and cash utilization at $110 million to $120 million, with plans for $12 million to $15 million of DTC spend, expansion of the EON inserter network and an ambition to double the U.S. patient base again.
Senseonics’ earnings call laid out a clear story of accelerating adoption and stronger unit economics, balanced by significant spending and execution risk as it scales. For investors, the key watchpoints will be patient retention, the efficiency of marketing and insertion networks, and the pace of European and pump‑integrated uptake as the company races to turn today’s heavy investments into tomorrow’s profitable growth.